West Cancer Center & Research Institute, a pioneer in radiology technology, now has a recently FDA-approved radiopharmaceutical agent: prostate-specific membrane antigen (PSMA).
This agent will be imaged with our state-of-art PET/CT imaging for men diagnosed with prostate cancer.
According to the American Cancer Society, 1 in 8 men will be diagnosed with prostate cancer during their lifetime with 268,490 new cases of prostate cancer forecasted for 2022 and approximately 34,500 deaths. As with any cancer, early detection is key to decreased morbidity, improved quality of life, and survivorship. At West, our Radiology department remains on the forefront for not only cancer detection but the latest advances in treatment.
While testing prostate specific antigen (PSA) levels has been a popular screening tool, additional testing is beneficial for a more accurate diagnosis. At West Cancer Center, detection and staging of this disease has expanded beyond conventional means with a new, FDA-approved, prostate-specific PET/CT using a radiopharmaceutical called PSMA that has a much wider indication for all stages of prostate cancer and has fewer payer restrictions.
West Cancer Center & Research Institute is proud to partner with providers in the community to serve their patients with a new, potentially live saving technology, all in a non-hospital setting.